Yesterday Axovant execs watched their stock price $AXON collapse after the biotech founded by the youthful former hedge fund manager Vivek Ramaswamy was forced to concede that its lead drug was worthless. Today, the company led by CEO David Hung followed up with the extraordinarily embarrassing admission that it managed to incorrectly report the p … Continue reading Axovant: That positive p-value we reported yesterday? Um, we screwed that up too